Glycoselect Investment opportunity

GlycoSeLect opens raising round for Irish investors

Dublin- GlycoSeLect has opened a private equity raising round, targeted at Irish tax resident investors.

Investors in the round may be able to avail of the Irish Revenue Commissioners’ Employment & Investment Incentive Scheme (EIIS) allowing them to obtain income tax relief on investments in qualifying Small and Medium Enterprises (SMEs).

The Irish government, through Enterprise Ireland and its other agencies, has been very supportive of companies during the COVID-19 pandemic. This finance round will facilitate further investment and grants to develop our RPL technology in biopharmaceutical manufacturing, especially vaccine and cancer immunotherapy applications.

For more information on this investment opportunity, please contact our CEO, Robert Dunne, by email robert.dunne@glycoselect.com or at GlycoSeLect Ltd phone number 01 2544164.

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories

Menu